The microchip-based implant is a self-contained hermetically-sealed drug delivery device that is easy to implant and remove in a physician’s office setting that can store 100’s of therapeutic doses over months and years, and release each dose at precise times. The device can be controlled by the patient and/or clinician via wireless remote or can be programmed to release drug on a pre-determined schedule.
The implant has been clinically-validated in human studies delivering PTH in osteoporosis patients and the most advanced version of the system is fully programmable via wireless communications to adjust dosing by the physician and/or patient.
The core technology was originated out of labs at MIT and now has 113 patents granted and 33 patent applications pending.
Method of Action
Each implant contains 100's of micro-reservoirs, small hermetically sealed compartments, each of which store up to 1 mg of drug. The microchip-based implant is activated by a wireless signal which triggers the micro-reservoirs to release the drug on a pre-programmed dosing schedule. In addition, the implant can be built with sensors that release drug in response to physiological or metabolic changes in the patient.
First-in-Human Clinical Trial of Microchip-based Implant
The microchip platform was tested in women with osteoporosis to deliver teriparatide, a synthetic parathyroid hormone (PTH) typically administered via daily injections to increase bone mass. The study, published in the peer-reviewed journal, Science Translational Medicine, found that women receiving teriparitide via the microchip-based implant absorbed the same therapeutic levels of the drug as observed in women who take daily injections (e.g., bioequivalent). In addition, the study found that the release profile of drug delivered via the microchip was more consistent from one dose to the next, compared to doses delivered via subcutaneous injection.